Merck KGgA has appointed Laszlo Radvanyi as senior vice president and head of research in immuno-oncology.
Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body’s immune system to fight cancer, as well as identifying biomarkers with the aim to deliver personalized treatments for patients.
Before joining Merck KGgA, Radvanyi served as chief scientific officer at Lion Biotechnologies based in Florida where he was responsible for developing new technologies to product next-generation TILs for tumor indications including lung, cervical and breast cancer.
Luciano Rossetti, head of global research and development, said: “We are honoured to have Laszio join Merck KGaA. His vast experience across the field of immuno-oncology research is very impressive.
“His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to bring new therapeutic options to patients living with cancer.”